<DOC>
	<DOCNO>NCT01148511</DOCNO>
	<brief_summary>The purpose study compare 2 treatment regimen patient suffer choroidal neovascularisation secondary age-related macular degeneration ( AMD ) . The first treatment regimen approve AMD treatment 1 injection month 3 month re-treatment patient visual loss 5 letter monthly control ( Treat Observe ) . The second treatment regimen 1 injection month 3 month extend control period macula dry monthly control ( Treat Extend ) . If `` Treat Extend '' regimen find effective safe , number ranibizumab injection , number patient visit , risk adverse event due intravitreal injection , policlinic occupation number could reduce .</brief_summary>
	<brief_title>Comparison Safety , Effectiveness Quality Life Outcomes Between Labeled Versus `` Treat Extend '' Regimen Turkish Patients With Choroidal Neovascularisation Due Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Male female patient age 50 . Patients primary , secondary , recurrent subfoveal choroidal neovascularization ( CNV ) AMD classic , minimal classic , occult lesion . Patients CNV area ≥ % 50 total lesion . Total lesion area ≤ 12 disc area minimal classic/occult lesion ≤ 9 disc area classic lesion . Bestcorrected visual acuity ( BCVA ) score 73 34 letter study eye . BCVA &lt; 34 letter . Patients use antiangiogenic drug ( pegaptanib , ranibizumab , anecortave acetate , corticosteroid , protein kinase C inhibitor , etc ) inclusion another trial ( eye ) . Verteporphin , external radiational therapy , subfoveal focal laser photocoagulation , vitrectomy , transpupillary thermotherapy application eye study . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Macula degeneration</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>Choroidal neovascularisation</keyword>
	<keyword>Treat extend</keyword>
	<keyword>Treat observe</keyword>
</DOC>